Our vision: Harnessing the immune system’s power to turn science into survival. Data Privacy: bit.ly/4fdYEf6 Imprint: bit.ly/3YmtoUr
Mainz, Germany
- Tweets 317
- Following 163
- Followers 79,263
- Likes 45
Lung cancer is not one disease.
Following #WCLC26, Dr.@StephenVLiu reflects on the complexity of lung cancer, how our understanding has evolved and why different strategies need to be explored to address the needs that remain.
Watch 👇
#LungCancer #CancerResearch
1
8
2,241
📢 Oncology news in 2L+ sqNSCLC: We presented the first median overall survival data from the PRESERVE-003 Phase 3 trial for a chemotherapy-free CTLA-4-targeting immunotherapy in 2L+ squamous non-small cell lung cancer.
🔗 Learn more: bit.ly/4h5DjqL
#LungCancer #WCLC26
1
3
29
3,037
We are excited to share new clinical data from our diversified lung cancer pipeline, including the first combination data for any PD-(L)1xVEGF bispecific plus a B7H3 ADC in lung cancer.
🔗 Learn more: bit.ly/4gaKY7W
#LungCancer #Oncology #WCLC26 #BioNTech
6
4
47
4,320
📢 𝗤𝟮 𝟮𝟬𝟮𝟲 𝗲𝗮𝗿𝗻𝗶𝗻𝗴𝘀 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗻𝗱 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 𝘂𝗽𝗱𝗮𝘁𝗲
𝗟𝗶𝗻𝗸 𝘁𝗼 𝗽𝗿𝗲𝘀𝘀 𝗿𝗲𝗹𝗲𝗮𝘀𝗲 𝗮𝗻𝗱 𝗳𝗼𝗿𝘄𝗮𝗿𝗱-𝗹𝗼𝗼𝗸𝗶𝗻𝗴 𝘀𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁𝘀:
bit.ly/4h9thXn
1
1
12
3,018
We are building for the many within lung cancer. Through 16+ clinical trials, we are pursuing innovative therapeutic approaches across subtypes and biomarkers to advance progress where patients still need more.
Explore the many: bit.ly/3TuyK13
#WorldLungCancerDay
1
9
2,465
At #SGOAM26 we are presenting data from the largest trial to date to report results for a HER2-targeted ADC in recurrent HER2-expressing endometrial cancer.
Read more: bit.ly/4voJn42
#BioNTech #WomensCancer #GynecologicOncology
3
29
3,027
Tomorrow at #ELCC26, Dr. Kai He will share data from stage 1 of the global Phase 3 PRESERVE-003 clinical trial evaluating a tumor microenvironment-selective regulatory T cell depletion candidate targeting CTLA-4 in second-line or later therapy of squamous NSCLC.
1
2
13
2,305
Tomorrow at #ELCC26, @bensolomon1 will share the global Phase 2/3 ROSETTA Lung-02 trial design evaluating a PD-L1xVEGF-A bispecific immunomodulator plus chemotherapy in first-line non-small cell lung cancer (NSCLC).The candidate is being developed by BioNTech and @bmsnews
1
4
16
2,740
At the #ELCC2026, we will present new clinical data from our late-stage portfolio across various #lungcancer subtypes and lines of treatment, reinforcing the transformative potential of our treatment approaches in this critical area.
👉bit.ly/3NEw5zp
#nsclc #esclc
1
6
1,562
📢 JPM 2026|Strategic areas of focus
Oncology milestones in 2026:
- 7 late-stage data readouts
- 6 Phase 3 clinical trial initiations expected
- Focus on high-incidence indications, such as lung and breast cancer
📰 bit.ly/3YY5I9L
🎥 bit.ly/3YY5I9L
#JPM2026
5
29
4,404